Education
About Us
Working with TipRanks
Follow Us
ALX Oncology Holdings (ALXO)
NASDAQ:ALXO
ALXO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.46 - $17.83
Previous CloseN/A
Volume579.15K
Average Volume (3M)524.09K
Market Cap
$31.65M
Enterprise Value-$35.31M
Total Cash (Recent Filing)$17.57M
Total Debt (Recent Filing)$9.90M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
May 08, 2025EPS Estimate
-0.47Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.60
Shares Outstanding53,384,144
10 Day Avg. Volume489,493
30 Day Avg. Volume524,085
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.27
Forecast
1Y Price Target
$4.63Price Target Upside698.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
---
ALX Oncology Holdings News
PremiumCompany Announcements
ALX Oncology Reports 2024 Financial Results and Updates---
Bulls Say, Bears Say
Bulls Say
Market OpportunityEvorpacept's commercial potential across multiple indications suggests a strong future market presence.
Research And DevelopmentAnnounced new trials with Evorpacept for breast and colorectal cancer, highlighting ongoing research and development efforts.
Bears Say
Competitive LandscapeModel changes lower the peak penetration rate estimate in Head and Neck cancer due to the evolving competitive landscape.
Financial SustainabilityALX Oncology has approximately 1.3 years of cash left, which may raise concerns about the company's financial sustainability.
Investor SentimentShort interest in the stock is relatively high, indicating some investor skepticism.
---
Ownership Overview
3.52% Insiders
5.59% Mutual Funds
38.81% Other Institutional Investors
45.95% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALXO FAQ
What was ALX Oncology Holdings’s price range in the past 12 months?
ALX Oncology Holdings lowest stock price was $0.46 and its highest was $17.82 in the past 12 months.
What is ALX Oncology Holdings’s market cap?
ALX Oncology Holdings’s market cap is $31.65M.
When is ALX Oncology Holdings’s upcoming earnings report date?
ALX Oncology Holdings’s upcoming earnings report date is May 08, 2025 which is in 13 days.
How were ALX Oncology Holdings’s earnings last quarter?
ALX Oncology Holdings released its earnings results on Mar 06, 2025. The company reported -$0.55 earnings per share for the quarter, beating the consensus estimate of -$0.67 by $0.12.
Is ALX Oncology Holdings overvalued?
According to Wall Street analysts ALX Oncology Holdings’s price is currently Undervalued.
Does ALX Oncology Holdings pay dividends?
ALX Oncology Holdings does not currently pay dividends.
What is ALX Oncology Holdings’s EPS estimate?
ALX Oncology Holdings’s EPS estimate is -0.47.
How many shares outstanding does ALX Oncology Holdings have?
ALX Oncology Holdings has 53,384,144 shares outstanding.
What happened to ALX Oncology Holdings’s price movement after its last earnings report?
ALX Oncology Holdings reported an EPS of -$0.55 in its last earnings report, beating expectations of -$0.67. Following the earnings report the stock price went down -19.084%.
Which hedge fund is a major shareholder of ALX Oncology Holdings?
Currently, no hedge funds are holding shares in ALXO
---
ALX Oncology Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.63 (698.28% Upside)
$4.63 (698.28% Upside)
Blogger Sentiment
Bullish
ALXO Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 96.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.8%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-96.29%
12-Months-Change
Fundamentals
Return on Equity
-88.91%
Trailing 12-Months
Asset Growth
-39.08%
Trailing 12-Months
Company Description
ALX Oncology Holdings
ALX Oncology Holdings Inc. (ALXO) is a clinical-stage immuno-oncology company focusing on the development of therapies designed to enhance the immune system's ability to eliminate cancer. The company's main product candidate, evorpacept (also known as ALX148), is a CD47-blocking therapeutic aimed at preventing cancer cells from evading the immune system. ALX Oncology operates within the biotechnology and pharmaceutical sectors, targeting various solid tumors and hematologic malignancies.
---
ALXO Stock 12 Month Forecast
Average Price Target
$4.63
▲(698.28% Upside)
Technical Analysis
Best Analysts Covering ALXO
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-36.97%
reiterated a buy rating 2 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -36.97% per trade.
---